CN113528570A - Method for evaluating pathogenicity of genetic variation by using migration function of mutant cells and application - Google Patents

Method for evaluating pathogenicity of genetic variation by using migration function of mutant cells and application Download PDF

Info

Publication number
CN113528570A
CN113528570A CN202110779589.XA CN202110779589A CN113528570A CN 113528570 A CN113528570 A CN 113528570A CN 202110779589 A CN202110779589 A CN 202110779589A CN 113528570 A CN113528570 A CN 113528570A
Authority
CN
China
Prior art keywords
elmo1
gene
mutant
neutrophils
pathogenicity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN202110779589.XA
Other languages
Chinese (zh)
Other versions
CN113528570B (en
Inventor
莫桂玲
薛容涛
徐进
孙明明
范喜杰
王莹
吕美
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
South China University of Technology SCUT
Guangzhou Kingmed Diagnostics Central Co Ltd
Original Assignee
South China University of Technology SCUT
Guangzhou Kingmed Diagnostics Central Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by South China University of Technology SCUT, Guangzhou Kingmed Diagnostics Central Co Ltd filed Critical South China University of Technology SCUT
Priority to CN202110779589.XA priority Critical patent/CN113528570B/en
Publication of CN113528570A publication Critical patent/CN113528570A/en
Application granted granted Critical
Publication of CN113528570B publication Critical patent/CN113528570B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/65—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression using markers
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/05—Animals modified by non-integrating nucleic acids, e.g. antisense, RNAi, morpholino, episomal vector, for non-therapeutic purpose
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/15—Humanized animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/40—Fish
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0306—Animal model for genetic diseases
    • A01K2267/0325—Animal model for autoimmune diseases
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/035—Animal model for multifactorial diseases
    • A01K2267/0362—Animal model for lipid/glucose metabolism, e.g. obesity, type-2 diabetes
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/035—Animal model for multifactorial diseases
    • A01K2267/0368—Animal model for inflammation
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0393—Animal model comprising a reporter system for screening tests
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/60—Fusion polypeptide containing spectroscopic/fluorescent detection, e.g. green fluorescent protein [GFP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/106—Plasmid DNA for vertebrates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A40/00—Adaptation technologies in agriculture, forestry, livestock or agroalimentary production
    • Y02A40/80—Adaptation technologies in agriculture, forestry, livestock or agroalimentary production in fisheries management
    • Y02A40/81—Aquaculture, e.g. of fish

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Veterinary Medicine (AREA)
  • Environmental Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Animal Husbandry (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

The invention relates to a method for evaluating pathogenicity of genetic variation by using a migration function of mutant cells and application thereof, belonging to the technical field of animal model construction. The method comprises the following steps: constructing an expression system for specifically expressing human ELMO1 gene variation sites by neutrophils: cloning a plasmid carrying a gene variation site sequence to be evaluated into an ELMO1 gene deletion zebra fish mutant model, and specifically expressing the ELMO1 gene variation site to be evaluated in neutrophils; time-lapse live imaging: and visually tracking the neutrophils carrying the ELMO1 gene variation site in the zebra fish gene deletion mutant model through delayed living imaging, and evaluating the influence of the gene variation site on the migration function of the neutrophils, thereby evaluating the pathogenicity of the gene variation site. The method can be used for identifying the functional change of the genetic variation based on the animal model, does not depend on the sample of a patient, and has the advantages of convenience in data acquisition and storage and high experimental repeatability and accuracy.

Description

Method for evaluating pathogenicity of genetic variation by using migration function of mutant cells and application
Technical Field
The invention relates to the technical field of animal model construction, in particular to a method for evaluating pathogenicity of genetic variation by using a mutant cell migration function and application thereof.
Background
ELMO1 protein translated from ELMO1 gene interacts with DOCK2 protein complex and is involved in regulating cell motility function by regulating RAC protein activity.
In the past decade, with the advent of high-throughput genome sequencing, human genome information has rapidly accumulated. In contrast to the fact that the deletion of the Dock2 gene has been reported to be associated with congenital immunodeficiency diseases, analysis of the gene polymorphism of ELMO1 in different populations around the world has found that the ELMO1 gene is rather associated with autoimmune diseases such as diabetes, inflammatory arthritis, and kidney diseases. Although the ELMO1 gene plays a role in regulating cell movement through an ELMO1-DOCK2-RAC1 ternary complex, the research of mice and cell lines shows that the cell migration function is damaged due to the mutation of the ELMO1 gene, the accumulation quantity of neutrophils at a chronic inflammation part in an ELMO1 gene-deleted mouse is obviously reduced compared with that of a wild type. This chemotactic deficiency of neutrophils, in turn, leads to a good prognosis of autoimmune diseases. In the research of inflammatory enteritis caused by salmonella infection, bacterial internalization of macrophages of mice with ELMO1 gene defects is weakened, so that bacterial burden in intestinal tracts of the mice is reduced, intestinal inflammatory reaction is caused, and disease progression is delayed.
The research on the ELMO1 gene in the mouse model is combined with the gene polymorphism analysis of the population carrying the ELMO1 gene mutation, and the ELMO1 protein with high expression level can be used as an index of disease progression to predict the poorer prognosis of the disease. Bioinformatic data from clinical specimens suggest that the ELMO1 gene affects disease progression by affecting immune cell chemotaxis for inflammation.
However, how these ELMO1 gene mutations present in the population affect immune cell function still requires more specific functional validation to confirm their relationship to disease susceptibility. In previous practice, researchers have isolated neutrophils directly from patient whole blood cells and tested these neutrophils carrying the ELMO1 mutation for their migratory capacity in vitro to identify their pathogenicity. In addition to in vitro experiments, in vivo functional verification of gene mutants using animal models is an indispensable strategy for providing more reliable disease counseling for clinical use.
In summary, the detection and identification of how a specific genetic variation site affects cell movement is based on the collection of an original sample of a patient, which is not favorable for large-scale screening of the variation site, and has the advantages of high cost, low repeatability and large required manpower and material resources. Therefore, it is urgent to provide a convenient and accurate animal model for diagnostic identification of specific gene mutation sites. Zebrafish, as a vertebrate highly conserved with both mice and humans, have successfully constructed a number of human disease models for large-scale drug screening. However, the research on the pathogenicity of specific genetic variation by using a zebra fish model is still very limited. Most of researches are carried out based on easily-detected indexes such as bleeding, heart structural abnormality, electrophysiology and the like, the researches can be carried out in mice, and the advantages of zebra fish as a model are not completely reflected.
Disclosure of Invention
Therefore, there is a need to provide a method for evaluating pathogenicity of genetic variation by using a mutant cell migration function, which can identify the functional change of a genetic variation site based on an animal model, is independent of a patient sample, and has the advantages of convenient data acquisition and storage, and high experimental repeatability and accuracy.
A method for assessing the pathogenicity of genetic variation based on the migration function of mutant cells, comprising the steps of:
constructing an expression system for specifically expressing human ELMO1 gene variation sites by neutrophils: cloning a plasmid carrying a gene variation site sequence to be evaluated into an ELMO1 gene deletion zebra fish mutant model by a microinjection method, and specifically expressing the ELMO1 gene variation site to be evaluated in neutrophils under the drive of a neutrophil specific promoter lyz so as to obtain a zebra fish gene variation site expression system;
time-lapse live imaging: and visually tracking the neutrophils carrying the ELMO1 gene variation site in the zebra fish gene deletion mutant model through delayed living imaging, and evaluating the influence of the gene variation site on the migration function of the neutrophils through the movement record of the neutrophils so as to evaluate the pathogenicity of the gene variation site.
In one embodiment, in the zebrafish mutant model with the ELMO1 gene deletion, the migration function of neutrophils is determined by the expression of the mutation site of the human ELMO1 gene.
In one embodiment, the zebrafish mutant model with the ELMO1 gene deletion is a mutant with a knockout sequence shown as SEQ ID No. 1.
In one embodiment, the genetic variation sites to be evaluated are: p.E90K, p.D194G or p.R354X.
In one embodiment, in the step of constructing an expression system for specifically expressing human ELMO1 gene mutation sites, after the neutrophil-specific promoter lyz, a fusion protein of human ELMO1 protein and fluorescent protein GFP is expressed, so that visual tracking of neutrophils in the expression system for human ELMO1 gene mutation sites is realized.
In one embodiment, in the delayed live imaging step, the migration path and migration speed of neutrophils expressing human ELMO1 gene mutation sites on the yolk sac of the zebra fish are recorded.
The invention also discloses application of the method for evaluating the pathogenicity of the genetic variation by using the migration function of the mutant cells in researching the pathogenicity of the genetic variation site of the human ELMO1 gene.
In one embodiment, the pathogenicity is a cause of impaired or hyperactivity of neutrophil motor function, thereby increasing susceptibility to an infectious or autoimmune disease.
In one embodiment, the increased infectious or autoimmune disease comprises a chronic infection, inflammatory bowel disease, rheumatoid arthritis, or diabetes.
The invention also discloses a biomarker for diseases caused by the damage of the migration function of neutrophils, wherein the biomarker is p.R354X.
The general concept of the invention is as follows:
1) a zebra fish ELMO1 gene deletion mutant which can be used for evaluating the pathogenicity of the human ELMO1 gene mutation site is constructed by utilizing a TALEN gene editing technology, and 13 pairs of base pairs are knocked out on a PH structural domain combined by the ELMO1 protein and the Dock2 protein. Deletion of base pairs causes a frameshift mutation resulting in a premature stop codon, resulting in loss of the PH domain and ultimately in loss-of-function gene mutants of the zebrafish Elmo1 protein.
2) After obtaining the zebrafish elmo1 gene deletion mutant, random movement of neutrophils in the yolk sac of three days after birth (3dpf) of zebrafish larvae was recorded using time-lapse in vivo imaging technique in combination with the stably expressed transgenic line Tg (lyz: DsRed) capable of specifically labeling neutrophils in the mutant. After shooting is finished, tracking and measuring the cell track by using image analysis processing software ImageJ, and statistically comparing the difference of the zebra fish elmo1 gene deletion mutant and the neutrophil migration function of the homozygote type and wild type zebra fish.
3) Construction of Tg (lyz: elmo 1)zeP2A-GFP). The coding region of the zebra fish elmo1 is connected with the fluorescent protein GFP by utilizing the P2A self-cleavage peptide, and the obtained plasmid is injected into the embryo of the zebra fish in the single cell stage by a microinjection method, so that the visualization of the movement process of the neutrophil, which expresses the elmo1 gene, in the larva of the zebra fish can be realized. After the expression system was established, we recorded the random movement of neutrophils in the yolk sac of zebrafish larvae three days after birth (3dpf) using time-lapse in vivo imaging techniques. After shooting is finished, tracking and measuring a cell track by using image analysis processing software ImageJ, and statistically analyzing whether the ELMO1 gene regulates the migration function of neutrophils due to a cell autonomous mechanism, wherein the cell track is used as an experimental basis for constructing a human ELMO1 gene variation site transient expression system to evaluate the pathogenicity of a gene variation site.
4) Construction of Tg (lyz: ELMO 1)hu-WTGFP). The coding region of the human ELMO1 gene is directly connected with fluorescent protein GFP to form ELMO1-GFP fusion protein, and the obtained plasmid is injected into the zebra fish single-cell-stage embryo by a microinjection method, so that the visual tracking of the neutrophils expressing the human ELMO1 gene is realized. After the expression system was established, we recorded the random movement of neutrophils in the yolk sac of zebrafish larvae three days after birth (3dpf) using time-lapse in vivo imaging techniques. After shooting is finished, tracking and measuring the cell track by using image analysis processing software ImageJ, and statistically analyzing whether the human ELMO1 gene is highly conserved with zebra fish ELMO1 gene, so that the function of regulating and controlling neutrophil migration can be realized, and the method is used as an experimental basis for constructing a human ELMO1 gene variation site transient expression system to evaluate the pathogenicity of gene variation sites.
5) Construction of Tg (lyz: ELMO 1)hu-VUSGFP). We refer to the three human ELMO1 gene variation sites: p.E90K (c.268G)>A)、p.D194G(c.581A>G) And p.R354X (c.1060C)>T) coding region is directly connected with fluorescent protein GFP to form ELMO1hu-VUSGFP fusion proteinAnd injecting the obtained plasmid into the zebra fish single-cell-stage embryo by a microinjection method to realize visual tracking of the neutrophils expressing the human ELMO1 gene variation sites. After the expression system was established, we recorded the random movement of neutrophils in the yolk sac of zebrafish larvae three days after birth (3dpf) using time-lapse in vivo imaging techniques. After shooting is finished, tracking and measuring the cell track by using image analysis processing software ImageJ, and statistically analyzing whether the expression of the gene variation sites causes the change of the migration function of the neutrophils, thereby evaluating the pathogenicity of the gene variation sites.
Compared with the prior art, the invention has the following beneficial effects:
the method for evaluating the pathogenicity of the genetic variation by using the migration function of the mutant cells utilizes zebra fish as an animal model to carry out functional verification of the genetic variation site, has the characteristics of low cost and short experimental period, and is more convenient for large-scale screening compared with a mouse model.
The invention respectively carries out the overexpression experiments of specific gene variation sites through the gene mutation zebra fish and the wild zebra fish, observes the change of cell functions after the variation in vivo, more accurately evaluates the pathogenicity of the gene variation sites, shows that the neutrophil movement speed of the zebra elmo1 gene mutant is obviously slowed down, and can be used for evaluating the influence of the gene variation on the granulocyte movement speed
The method can perform over-expression of various types of variation of specific genes in specific cells (neutrophils), can be used for evaluating the function change of gene mutation on a certain specific cell, and has higher accuracy and specificity.
The method utilizes the transparent juvenile zebra fish to observe the movement of the cells in real time, can completely record the movement process of the cells through software, makes up the singleness of in vitro experiments, covers the complex regulation and control relationship in vivo through in vivo real-time observation, and can more accurately evaluate the change of the cell function caused by gene variation;
and the method identifies the functional change of the genetic variation based on the animal model, does not depend on the sample of the patient, is convenient for data acquisition and storage, and has high experimental repeatability and accuracy.
By the evaluation of the invention, the potential possibility of the development of diseases (such as infectious diseases or autoimmune diseases, including chronic infection, diabetes or rheumatoid arthritis and the like) which cause immunity by influencing the migration function of the neutrophils in the p.R354X is suggested.
Drawings
FIG. 1 is a schematic diagram of DNA sequencing results of zebrafish elmo1 gene deletion mutant and sibling wild type thereof and the corresponding formed proteins.
FIG. 2 is a schematic representation of phenotypic analysis of zebrafish elmo1 gene deletion mutants and sibling wild type (elmo1+/+), heterozygous (elmo +/-) zebrafish neutrophils.
FIG. 3 is a graph showing the results of a rescue experiment in which zebrafish elmo1 gene was expressed specifically in neutrophils in zebrafish elmo1 gene deletion mutant (elmo1-/-) and its sibling zebrafish (elmo1+/+ or elmo +/-).
FIG. 4 is a graph showing the results of a rescue experiment in which deletion mutants of the zebrafish ELMO1 gene (ELMO1-/-) and its sibling zebrafish (ELMO1+/+ or ELMO +/-) specifically express the human ELMO1 gene and its gene mutation sites in neutrophils.
FIG. 5 is a graph of the movement trace of neutrophils on the yolk sac of a mutant zebrafish and a sibling zebrafish at 3 dpf.
Detailed Description
To facilitate an understanding of the invention, the invention will now be described more fully with reference to the accompanying drawings. Preferred embodiments of the present invention are shown in the drawings. This invention may, however, be embodied in many different forms and should not be construed as limited to the embodiments set forth herein. Rather, these embodiments are provided so that this disclosure will be thorough and complete.
Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. The terminology used in the description of the invention herein is for the purpose of describing particular embodiments only and is not intended to be limiting of the invention. As used herein, the term "and/or" includes any and all combinations of one or more of the associated listed items.
The reagents used in the following examples, unless otherwise specified, are all commercially available; the methods used in the following examples, unless otherwise specified, are all routinely practiced.
The terms "wild type" or "WT" as used herein both refer to wild type zebrafish.
The term "sib fish (sibing)" as used herein refers to an individual offspring from the same parent, either sib wild type or sib hybrid (elmo 1)+/+Or elmo+/-)。
In the following examples, in vivo imaging was performed by referring to the methods reported in the previous literature (Xu, J., Wang, T., Wu, Y., Jin, W., and Wen, Z. (2016.) Microglia immunization of Developing Zebraphish Midbrain Is protein by antigenic Neuron and lysophosphaticlocholine. Dev Cell 38, 214-222.).
Specifically, 3 days post fertilization (3dpf) larvae were anesthetized in 0.01% tricaine (A5040; Sigma-Aldrich), followed by fixing the anesthetized larvae in 1% low melting agarose and imaging the larvae on a Zeiss 880 confocal microscope with a 28 ℃ constant temperature and humidity incubator. We used a 10-fold objective lens for neutrophil tracking. The Z step size is set to 3 mm and 15-20 planes are typically acquired in the Z plane at intervals of less than 3 minutes. The images taken were image processed using ImageJ software and cell tracking analysis was performed using MTrackJ plug-in. And extracting the tracking path of the single cell from the derived tracking result, and carrying out image layer combination by using Photoshop software. The derived cell movement velocity data was subjected to statistical analysis using statistical software Prism 7.
Examples
1. Zebra fish culture
Zebra fish breeding was carried out according to The method reported in The literature (Westerfield M: The zebrafish: guide for The laboratory use of zebrafish (Brachdanio relay.) Edition by Eugene, OR, M.Westerfield, 1993).
The following zebra fish strains are used in the invention:
ABSR wild type zebra fish, transgenic line Tg (lyz: DsRed), elmo1 gene deletion zebra fish mutant Tg (lyz: DsRed): from the Zilong Wen laboratory (L.Li, B.Yan, Y.Q.Shi, W.Q.Zhang, Z.L.Wen, Live imaging differentiation roles of macrohages and neutrophiles duringzebraf tail fine regeneration. J Biol Chem 287,25353 + 25360 (2012)).
The zebra fish mutant with the elmo1 gene deleted is characterized in that a target site on exon 18 of an elmo1 gene (NC-007130.7) is designed by using a TALEN gene editing technology. 13 base pairs (GCCCTCAGGGAGA, SEQ ID NO.1) are knocked out on the PH domain of the zebra fish Elmo1 protein and the Dock2 protein in combination by using the technology. Deletion of base pairs causes a frameshift mutation resulting in a premature stop codon, resulting in loss of the PH domain and ultimately in loss-of-function gene mutants of the zebrafish Elmo1 protein.
FIG. 1 is a schematic diagram of DNA sequencing results of an elmo1 gene deletion mutant of zebrafish and a sibling wild type DNA thereof and a protein formed correspondingly, wherein a diagram A represents a schematic diagram of an elmo1 genomic locus (NC-007130.7). The extended region on exon 18 represents the sequence targeted by the TALEN system. The left light grey sequence indicates the TALEN arm binding site. The light grey sequence on the right indicates the TALEN arm binding site. The dark sequence in the middle of the two is the spacer site. elmo1+/+Corresponding to the sibling wild type, whereas elmo1-/-Represents a loss-of-function mutant. Dashes represent deletions of 13 base pairs. Panel B represents a schematic representation of wild type (Elmo1 wt) and mutant Elmo1 protein (Elmo1 mut). Of these, Elmo1 wt of 726 amino acids (aa) contains five conserved domains (NP-998256), while Elmo1 mut results in a truncated protein ending at 619 aa. RBD represents the RhoG protein binding domain; EID represents the ELMO inhibitory domain; ELMO1 represents the ELMO1 domain; PH represents pleckstrin homeodomain; EAD represents the ELMO autoregulation domain.
2. Establishment of Gene mutation site expression System
2.1 establishment of expression System for neutrophil-specific expression of the zebrafish elmo1 Gene
In order to specifically express the zebrafish Elmo1 gene in neutrophils, we selected the lyz promoter according to literature reports, linked the coding region of the zebrafish Elmo1 gene (NM _213091.1) after the lyz promoter, and linked the zebrafish Elmo1 protein and the green fluorescent protein GFP using P2A self-cleaving peptide. We cloned the above components into the vector PBLK-sv40 plasmid. The final plasmid obtained: PBLK-lyz Elmo1zeP2A-GFP-sv40 by microinjection, 1.8nl (40 ng/. mu.l) of plasmid was injected into the single-cell-stage elmo1 gene deletion mutant and the sibling zebrafish embryos, and the zebrafish embryos were cultured to 3 days after birth (3dpf), and a delayed in vivo imaging experiment was performed to analyze whether the zebrafish elmo1 gene regulates the neutrophil migration function by a cell autonomous mechanism.
FIG. 2 shows zebrafish elmo1 gene deletion mutants and sibling wild type (elmo 1)+/+) Hybrid type (elmo)+/-) Phenotypic analysis of zebrafish neutrophils. Wherein Panel A is the sibling wild type (elmo 1)+/+) And mutant (elmo 1)-/-) And (5) in-situ hybridization result of the zebra fish. Panel B shows the number of neutrophil signals, as shown in Panel A and Panel B, mutant (elmo 1) compared to siblings-/-) The number of neutrophils was not significantly changed. Panel C shows the movement trajectories of neutrophils labeled with Tg (lyz: DsRed) on yolk sac at 3dpf for sibling wild type, heterozygous and mutant zebrafish. Wherein each successive line represents the movement trajectory of each different neutrophil. Panel D is a statistical result of neutrophil migration function, showing a significant decrease in neutrophil migration velocity in mutant zebrafish compared to sibling wild-type and heterozygous zebrafish. (one-way ANOVA, ns: no significant differences.)
Subsequently, a rescue experiment was carried out, namely that the zebrafish elmo1 gene was expressed in an elmo1 gene deletion mutant, and the result is shown in fig. 3.
FIG. 3 shows deletion mutants of the zebrafish elmo1 gene (elmo 1)-/-) And its sibling zebrafish (elmo 1)+/+Or elmo+/-) Is specifically inRescue experiment results for expressing zebrafish elmo1 gene in sex granulocytes. Wherein panel A shows the Tg of the yolk sac at 3dpf for mutant and sibling zebrafish (lyz: elmo 1)zeP2A-GFP) in a single cell. Wherein each successive line represents the movement trajectory of each different neutrophil. Panel B is a statistical result of neutrophil migration function, showing that compared to the injection of control plasmid lyz: compared with the zebra fish with GFP, the neutrophil migration capability in the mutant is obviously recovered after the zebra fish elmo1 gene is expressed. (one-way anova, ns: no significant difference<0.001。)
The result proves that the damaged neutrophil migration function is recovered after the elmo1 gene deletion mutant expresses the zebrafish elmo1 gene, and the zebrafish elmo1 gene regulates the neutrophil migration function through a cell autonomous mechanism.
2.2 establishment of expression System for neutrophil-specific expression of human ELMO1 Gene
In order to specifically express the human ELMO1 gene in neutrophils, we selected the lyz promoter according to literature reports, as mentioned above. And the coding region (NM-014800.11) of the human ELMO1 gene is connected behind lyz promoter, and the human ELMO1 protein and the green fluorescent protein GFP are directly connected to obtain the ELMO1-GFP fusion protein. We cloned the above components into the vector PBLK-sv40 plasmid. The final plasmid obtained: PBLK-lyz ELMO1huGFP-sv40(hu-WT) by microinjection, 1.8nl (40 ng/. mu.l) of plasmid was injected into the single-cell-stage Elmo1 gene deletion mutant and the sibling zebrafish embryos, and the zebrafish embryos were cultured to 3 days postnatal (3dpf) to perform a delayed in vivo imaging experiment to prove whether the human Elmo1 gene and zebrafish Elmo1 gene are highly conserved for the regulation of neutrophil migration function.
As shown in fig. 4C, the deletion mutant of ELMO1 gene restored the damaged neutrophil migration function after expressing human ELMO1 gene, demonstrating the high conservation of human ELMO1 gene and zebrafish ELMO1 gene in the regulation of neutrophil migration function. This result confirmed that it is feasible to use the zebrafish elmo1 gene mutant as a pathogenic animal model for evaluating the expression of gene variation sites.
2.3 establishment of expression System for neutrophil-specific expression of human ELMO1 Gene mutation site
(1) And (3) screening the human ELMO1 gene variation site.
ELMO1 gene mutation site information is searched from a clinical genetic database established by a previous detection sample of the inventor company, and the searched mutation site screening basis is as follows: the Mutation is annotated by VEP (variable Effect predictor) software, the Mutation sites are screened based on ClinVar, OMIM, HGMD, gnomaD and other hereditary disease databases, Mutation databases, thousand human genomes, ESP6500 and other population large-scale sequencing databases, and a plurality of computer algorithms (PolyPhen2, SIFT, Mutation Taster and the like) are adopted to predict and classify the pathogenicity Mutation.
The variation scores were classified with reference to "sequence variation interpretation standards and guidelines" issued by the american society for medical genetics and genomics (ACMG). 14 ELMO1 gene mutation sites classified as VUS were selected from the group, as shown in Table 1 below, wherein the 11-14 gene mutation sites are not conserved between humans and zebrafish and are not involved in the present invention. According to whether the property of amino acid is changed after the base variation of the gene, the No. 1-3 gene variation site is reserved for functional verification in the invention.
TABLE 1 ELMO1 Gene mutation site information
Figure BDA0003155887460000071
(2) The human ELMO1 gene variation site is specifically expressed in neutrophils.
To specifically express the human ELMO1 gene mutation site in neutrophils, the lyz promoter was selected as mentioned above. After base editing, the mutation sites of human ELMO1 genes with numbers 1-3 (p.E90K, p.D194G and p.R354X) are connected behind lyz promoters, and the human ELMO1 mutant protein and green fluorescent protein GFP are directly connected to obtain the ELMO1-GFP mutant fusion protein.
We cloned the above components into the vector PBLK-sv40 plasmid. The final plasmid obtained: PBLK-lyz ELMO1VUSGFP-sv40(p.E90K, p.D194G and p.R354X) 1.8nl (40 ng/. mu.l) of plasmid was injected into the unicellular ELMO1 gene deletion mutant and the sibling zebrafish embryos by microinjection, and the zebrafish embryos were cultured to 3 days postnatal (3dpf) for a delayed in vivo imaging experiment to analyze the pathogenicity of the human ELMO1 gene variation site.
The results are shown in FIGS. 4-5, and FIG. 4 shows deletion mutants of the zebrafish elmo1 gene (elmo 1)-/-) And its sibling zebrafish (elmo 1)+/+Or elmo+/-) The human ELMO1 gene and the gene variation site thereof are expressed in the neutrophils specifically. Panel A shows a protein schematic of the human ELMO1 gene, and the functional domain positions of the three gene variation sites involved in the present invention are indicated on the diagram. Panel B and C are statistics of neutrophil migration function. FIG. 5 shows the neutrophil movement tracks on the yolk sac of mutant and sibling zebrafish at 3 dpf. Panel B shows an injection of Tg bearing the coding region of the human ELMO1 gene (lyz: ELMO 1)hu-WTGFP) plasmid, the movement track of neutrophils in the zebrafish elmo1 mutant and its siblings, respectively. Panels C-E show the movement trajectories of neutrophils in the zebrafish ELMO1 mutant and siblings thereof after expression of three ELMO1 gene mutation sites of p.e90k, p.d194g and p.r354x, respectively, and each continuous line in the figures represents the movement trajectory of each different neutrophil.
The results show that after the expression of p.E90K and p.D194G, the migration function of the neutrophils in the mutant is recovered, while after the expression of p.R354X, the migration function of the neutrophils in the mutant cannot be recovered, and the migration function of the neutrophils in the zebra fish is inhibited. The statistical method in the figure adopts one-factor analysis of variance, ns: no significant difference, p < 0.001.
After the human ELMO1 gene variation site is expressed, p.E90K and p.D194G can recover the damaged neutrophil migration function in the zebra fish mutant, and the two gene variation sites have no strong obvious pathogenicity. And p.R354X can not restore damaged neutrophil migration function in the mutant zebra fish, and in addition, the normal neutrophil migration function in the sibling fish is influenced, so that the zebra fish mutant has obvious pathogenicity, namely pathological potential and is possibly related to the generation and development of chronic inflammation.
In conclusion, in the zebrafish elmo1 gene deletion mutant, the migration function of the sex granulocytes was impaired compared to that of the sibling wild type and heterozygous zebrafish. After the zebrafish elmo1 gene is expressed, the damaged neutrophil migration function in the mutant body is recovered. Human ELMO1 gene expression can also restore the function of damaged neutrophil migration in zebra fish mutant, and proves that human and zebra fish are highly conserved. Therefore, after the human ELMO1 gene variation site is expressed, p.E90K and p.D194G can recover the damaged neutrophil migration function in the zebra fish mutant, and the two gene variation sites have no strong obvious pathogenicity. And p.R354X can not restore damaged neutrophil migration function in the mutant zebra fish, and in addition, normal neutrophil migration function in the sibling fish is also influenced, which indicates that the zebra fish mutant has obvious pathogenicity, namely pathological potential.
The ELMO1 gene variant protein is transiently overexpressed in the zebra fish ELMO1 gene mutant, so that accurate evaluation of the gene variant on the cell movement capacity can be realized.
The technical features of the embodiments described above may be arbitrarily combined, and for the sake of brevity, all possible combinations of the technical features in the embodiments described above are not described, but should be considered as being within the scope of the present specification as long as there is no contradiction between the combinations of the technical features.
The above-mentioned embodiments only express several embodiments of the present invention, and the description thereof is more specific and detailed, but not construed as limiting the scope of the invention. It should be noted that, for a person skilled in the art, several variations and modifications can be made without departing from the inventive concept, which falls within the scope of the present invention. Therefore, the protection scope of the present patent shall be subject to the appended claims.
Sequence listing
<110> Guangzhou gold-area medical inspection center, Inc
South China University of Technology
<120> method for evaluating pathogenicity of gene variation by using migration function of mutant cell and application thereof
<160> 1
<170> SIPOSequenceListing 1.0
<210> 1
<211> 13
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 1
gccctcaggg aga 13

Claims (10)

1. A method for evaluating the pathogenicity of genetic variation by using the migration function of mutant cells, which is characterized in that:
constructing an expression system for specifically expressing human ELMO1 gene variation sites by neutrophils: cloning a plasmid carrying a gene variation site sequence to be evaluated into an ELMO1 gene deletion zebra fish mutant model by a microinjection method, and specifically expressing the ELMO1 gene variation site to be evaluated in neutrophils under the drive of a neutrophil specific promoter lyz so as to obtain a zebra fish gene variation site expression system;
time-lapse live imaging: and visually tracking the neutrophils carrying the ELMO1 gene variation site in the zebra fish gene deletion mutant model through delayed living imaging, and evaluating the influence of the gene variation site on the migration function of the neutrophils through the movement record of the neutrophils so as to evaluate the pathogenicity of the gene variation site.
2. The method of claim 1, wherein the ELMO1 gene deletion zebrafish mutant model is characterized in that the migration function of neutrophils is determined by the expression of the mutation site of human ELMO1 gene.
3. The method for evaluating the pathogenicity of genetic variation through the migration function of mutant cells according to claim 1, wherein the ELMO1 gene deletion zebrafish mutant model is a mutant with a knockout sequence shown as SEQ ID No. 1.
4. The method for evaluating the pathogenicity of a genetic variation based on the migration function of a mutant cell as claimed in claim 1, wherein the sites of the genetic variation to be evaluated are: p.E90K, p.D194G or p.R354X.
5. The method for evaluating the pathogenicity of a genetic variation through the migration function of a mutant cell, according to claim 1, wherein in the step of constructing the expression system for specifically expressing the mutation site of the human ELMO1 gene by the neutrophil, a fusion protein of the human ELMO1 protein and a fluorescent protein GFP is expressed after a neutrophil-specific promoter lyz, so that the visible tracking of the neutrophil in the expression system of the mutation site of the human ELMO1 gene is realized.
6. The method for assessing the pathogenicity of a genetic variation based on the migration function of a mutant cell of claim 1, wherein in the delayed in vivo imaging step, the migration path and the migration speed of neutrophils expressing the human ELMO1 genetic variation site on the yolk sac of the zebrafish are recorded.
7. Use of the method of any one of claims 1-6 for evaluating pathogenicity of genetic variation based on migration function of mutant cells in the study of pathogenicity of human ELMO1 genetic variation site.
8. Use according to claim 7, characterized in that: the pathogenicity is the damage or hyperfunction of the movement function of the neutrophil granulocytes, so that the susceptibility of infectious diseases or autoimmune diseases is increased.
9. Use according to claim 8, characterized in that: the increased infectious or autoimmune disease includes chronic infection, inflammatory bowel disease, rheumatoid arthritis or diabetes.
10. A biomarker for disease caused by impaired neutrophil migration function, characterized by: the biomarker is p.R354X.
CN202110779589.XA 2021-07-09 2021-07-09 Method for evaluating pathogenicity of genetic variation by using mutant cell migration function and application Active CN113528570B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202110779589.XA CN113528570B (en) 2021-07-09 2021-07-09 Method for evaluating pathogenicity of genetic variation by using mutant cell migration function and application

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202110779589.XA CN113528570B (en) 2021-07-09 2021-07-09 Method for evaluating pathogenicity of genetic variation by using mutant cell migration function and application

Publications (2)

Publication Number Publication Date
CN113528570A true CN113528570A (en) 2021-10-22
CN113528570B CN113528570B (en) 2023-08-01

Family

ID=78098304

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202110779589.XA Active CN113528570B (en) 2021-07-09 2021-07-09 Method for evaluating pathogenicity of genetic variation by using mutant cell migration function and application

Country Status (1)

Country Link
CN (1) CN113528570B (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114496072A (en) * 2022-01-17 2022-05-13 北京安琪尔基因医学科技有限公司 Deafness pathogenic analysis grade classification method and device, computer readable storage medium and server

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060234294A1 (en) * 2002-11-26 2006-10-19 Japan Science And Technology Agency Functional domain and associated molecule of dock2 essentially required in lymphocyte migration
CN111264467A (en) * 2018-12-05 2020-06-12 华南理工大学 Application of mutant zebra fish in preparation of animal model of myelodysplastic syndrome

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060234294A1 (en) * 2002-11-26 2006-10-19 Japan Science And Technology Agency Functional domain and associated molecule of dock2 essentially required in lymphocyte migration
CN111264467A (en) * 2018-12-05 2020-06-12 华南理工大学 Application of mutant zebra fish in preparation of animal model of myelodysplastic syndrome

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
ARANDJELOVIC S, ET AL.: "A noncanonical role for the engulfment gene ELMO1 in neutrophils that promotes inflammatory arthritis", 《NAT IMMUNOL.》 *
HENRY KM, ET AL.: "Zebrafish as a model for the study of neutrophil biology", 《J LEUKOC BIOL.》 *
MIRIAM A. SHELEF, ET AL.: "Neutrophil migration: moving from zebrafish models to human autoimmunity", 《IMMUNOLOGICAL REVIEWS》 *
WANG X, ET AL.: "Inhibitors of neutrophil recruitment identified using transgenic zebrafish to screen a natural product library", 《DIS MODEL MECH.》 *
ZANANDREA R, ET AL.: "Zebrafish as a model for inflammation and drug discovery", 《DRUG DISCOV TODAY》 *
无: "rs759455617", 《NCBI》 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114496072A (en) * 2022-01-17 2022-05-13 北京安琪尔基因医学科技有限公司 Deafness pathogenic analysis grade classification method and device, computer readable storage medium and server

Also Published As

Publication number Publication date
CN113528570B (en) 2023-08-01

Similar Documents

Publication Publication Date Title
Werner et al. Cxcr4 distinguishes HSC-derived monocytes from microglia and reveals monocyte immune responses to experimental stroke
Ray et al. Comprehensive identification of mRNA isoforms reveals the diversity of neural cell-surface molecules with roles in retinal development and disease
Märtin et al. A spatiomolecular map of the striatum
Mo et al. Epigenomic landscapes of retinal rods and cones
Murat et al. The molecular evolution of spermatogenesis across mammals
Zuo et al. p63+ Krt5+ distal airway stem cells are essential for lung regeneration
Naert et al. CRISPR/Cas9 disease models in zebrafish and Xenopus: The genetic renaissance of fish and frogs
JP5670755B2 (en) Methods and compositions for translation profiling and molecular phenotyping
Hou et al. Heterogeneity in endothelial cells and widespread venous arterialization during early vascular development in mammals
Cañestro et al. Consequences of lineage-specific gene loss on functional evolution of surviving paralogs: ALDH1A and retinoic acid signaling in vertebrate genomes
Li et al. Generation of Tβ4 knock-in Cashmere goat using CRISPR/Cas9
Derk et al. Formation and function of the meningeal arachnoid barrier around the developing mouse brain
Cai et al. Aging-associated lncRNAs are evolutionarily conserved and participate in NFκB signaling
Seleit et al. Development and regeneration dynamics of the Medaka notochord
CN113528570A (en) Method for evaluating pathogenicity of genetic variation by using migration function of mutant cells and application
Lynch et al. Notch-dependent DNA cis-regulatory elements and their dose-dependent control of C. elegans stem cell self-renewal
Mah et al. ING4 and ING5 are essential for histone H3 lysine 14 acetylation and epicardial cell lineage development
Diri et al. The nucleome of developing murine rod photoreceptors
Zhang et al. Tnni1b-ECR183-d2, an 87 bp cardiac enhancer of zebrafish
Xue et al. Functional verification of novel ELMO1 variants by live imaging in Zebrafish
Singh et al. The Blepharisma stoltei macronuclear genome: towards the origins of whole genome reorganization
Martins-Costa et al. ARID1B controls transcriptional programs of axon projection in the human corpus callosum
CN114946765B (en) Zebra fish model for congenital thrombocytopenia syndrome and application thereof
Kirchberger et al. Comparative transcriptomics coupled to developmental grading via transgenic zebrafish reporter strains identifies conserved features in neutrophil maturation
Cranley et al. Multiomic analysis reveals developmental dynamics of the human heart in health and disease

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information

Address after: No. 10, Helix 3 Road, International Biological Island, Huangpu District, Guangzhou City, Guangdong Province, 510320

Applicant after: GUANGZHOU KINGMED CENTER FOR CLINICAL LABORATORY

Applicant after: SOUTH CHINA University OF TECHNOLOGY

Address before: 510335 3rd floor, 2429 Xingang East Road, Haizhu District, Guangzhou City, Guangdong Province

Applicant before: GUANGZHOU KINGMED CENTER FOR CLINICAL LABORATORY

Applicant before: SOUTH CHINA University OF TECHNOLOGY

CB02 Change of applicant information
GR01 Patent grant
GR01 Patent grant